Skip to main content

Table 3 Argatroban therapy

From: Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study

Patient HIPA test Platelet count (×1,000/μL) INR before A INR after A aPTT before A (sec) aPTT after A (sec) aPTT mean during A therapy (sec) A starting dose (μg/kg/min) A mean dose (μg/kg/min)
1 + 93 1.2 1.6 44 80 68.4 0.08 0.02
2 + 48 0.8 1.2 39 62 56.3 0.48 0.48
3 - 18 1.1 1.6 63 106 88.7 0.56 0.37
4 + 9 2.1 1.5 79 57 93.2 0.22 0.15
5 + 38 1.1 1.6 29 51 36.4 0.04 0.14
6 - 31 1.0 1.0 48 51 60.5 0.14 0.14
7 - 87 1.1 1.4 46 53 62.5 0.46 0.46
8 - 46 1.2 1.6 52 87 61.3 0.83 0.30
9 - 19 1.9 1.9 54 63 63.0 0.08 0.08
10 - 15 1.1 1.6 58 75 67.5 0.56 0.42
11 + 90 1.0 1.5 42 56 68.5 0.22 0.20
12 + 58 1.2 1.4 36 47 51.5 0.14 0.14
  6+/6- 46 ± 30 1.23 ± 0.38 1.49 ± 0.23 49 ± 13 66 ± 18 64.8 ± 15.1 0.32 ± 0.25 0.24 ± 0.16
  1. For each patient (pt), HIPA-test results (+, positive, - = negative), platelet count (×1,000 per microliter), INR/aPTT values before argatroban therapy, and INR/aPTT values at first assessment after starting argatroban are provided. Mean aPTTs during argatroban therapy, argatroban starting doses, and argatroban mean doses are shown. Data are provided for each patient and as mean ± SD where possible. A, argatroban; aPTT, activated partial thromboplastin time; HIPA, heparin-induced platelet activation; INR, International Normalized Ratio.